SecBot SecBot
8-K ·Filed Apr 17, 2026

ZNTL

Zentalis Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001725160-26-000020
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The compelling preclinical data in TNBC, particularly in ADC-resistant models, suggests azenosertib could address a growing unmet need as ADCs move into first-line TNBC treatment. This pipeline expansion potential, combined with strong validation of the ovarian cancer target population, could drive positive re-rating. Monitor for clinical trial initiation in TNBC and upcoming data from ongoing ovarian cancer studies.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.64
T+0 close · Apr 17, 2026 · via day close
Latest settled
+2.80%
T+60 · $4.77
Vs SPY
−3.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $4.64entry
  2. T+1 · 7mo ago −13.15%α −12.95% · $4.03
  3. T+5 · 7mo ago −14.22%α −14.78% · $3.98
  4. T+20 · 6mo ago −11.85%α −17.22% · $4.09
  5. T+60 · 4mo ago +2.80%α −3.34% · $4.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis Pharmaceuticals presented preclinical data at AACR 2026 showing that its investigational WEE1 inhibitor azenosertib demonstrates strong antitumor activity in triple-negative breast cancer (TNBC), including complete responses in ADC-resistant models. The company also presented real-world evidence confirming poor outcomes for Cyclin E1-positive ovarian cancer patients, reinforcing the unmet need for azenosertib in this population.

Key Facts

  • Azenosertib combinations induced complete tumor responses in 7 of 8 mice (87.5%) in a TNBC model resistant to sacituzumab govitecan
  • Prevented tumor progression in 8 of 8 mice for over 52 days vs. 100% progression within 30 days with enfortumab vedotin alone
  • Azenosertib monotherapy showed 42-99% tumor growth inhibition across 12 TNBC models
  • Cyclin E1-positive ovarian cancer patients had significantly worse outcomes: 13.2-14.9 months time to next treatment vs. 19.5 months for Cyclin E1-negative patients (p<0.002)
  • Azenosertib has Fast Track Designation from FDA for Cyclin E1-positive platinum-resistant ovarian cancer

Financial Impact

Potential pipeline expansion into TNBC market, which could significantly increase peak sales potential beyond current ovarian cancer focus

pipeline valuemarket opportunitydevelopment risk

Risk Factors

  • Preclinical data may not translate to human clinical efficacy
  • Competitive landscape in TNBC is rapidly evolving with multiple ADCs and targeted therapies in development
  • Company has limited financial resources and may need to raise capital

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001725160-26-000020
Exhibit: ex991aacr2026datapressrele.htm0001725160-26-000020
Exhibit: ex993-jeongetal_realworl.htm0001725160-26-000020
Exhibit: ex992-leeetalazenointnbc.htm0001725160-26-000020
Document: 0001725160-26-000020-index-headers.html0001725160-26-000020
Document: 0001725160-26-000020-index.html0001725160-26-000020
Document: 0001725160-26-000020.txt0001725160-26-000020

Track record

18 reports on ZNTL

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026